Insulin tregopil - Biocon
Alternative Names: GW 843362; Hexyl Insulin M2; Hexyl insulin monoconjugate 2; HIM2; IN-105; NIN-058; Oral prandial insulin - BioconLatest Information Update: 13 Sep 2024
At a glance
- Originator Nobex Corporation
- Developer Biocon; Bristol-Myers Squibb
- Class Antihyperglycaemics; Hormones; Insulins; Peptides
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Type 2 diabetes mellitus
- Phase II Type 1 diabetes mellitus
Most Recent Events
- 16 Jun 2023 Phase-Ib development is ongoing Germany (PO, Tablet) (Biocon pipeline, June 2023)
- 27 Jun 2022 Biocon terminates a phase I trial in Type 1 diabetes mellitus in Germany (PO), before starting part 2 of study (NCT04141423)
- 28 Oct 2019 Phase-I clinical trials in Type 1 diabetes mellitus in Germany (PO) (NCT04141423)